Sequence-specific modifications enhance the broad-spectrum antiviral response activated by RIG-I agonists

Journal of Virology

Volumn 89, Issue 15, 2015, Pages 8011-8025

  Chiang, Cindy ^a   Beljanski, Vladimir ^a   Yin, Kevin ^a   Olagnier, David ^a,c   Yebdri, Fethia Ben ^c   Steel, Courtney ^a   Goulet, Marie Line ^c   DeFilippis, Victor R ^b   Streblow, Daniel N ^b   Haddad, Elias K ^a   Trautmann, Lydie ^a   Ross, Ted ^a   Lin, Rongtuan ^c   Hiscott, John ^a  

^a Vaccine and Gene Therapy Institute of Florida   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; APTAMER; M 8; OSELTAMIVIR; POLYINOSINIC POLYCYTIDYLIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; RETINOIC ACID INDUCIBLE PROTEIN I AGONIST; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; DDX58 PROTEIN, HUMAN; DEAD BOX PROTEIN; VIRUS RNA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHEMICAL MODIFICATION; CHEMOPROPHYLAXIS; CHIKUNGUNYA; CONTROLLED STUDY; CYTOKINE RESPONSE; DENGUE VIRUS; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; EPITHELIUM CELL; FOOT; FOOT EDEMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLUENZA A (H5N1); INFLUENZA VIRUS; INFLUENZA VIRUS A H5N1; INNATE IMMUNITY; LUNG ALVEOLUS EPITHELIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SEQUENCE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; CHIKUNGUNYA VIRUS; CONFORMATION; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); VIROLOGY; VIRUS INFECTION;

CHIKUNGUNYA VIRUS; DENGUE VIRUS; MURINAE; MUS; ORTHOMYXOVIRIDAE; RNA VIRUSES;

ANIMALS; CELL LINE; CHIKUNGUNYA VIRUS; DEAD-BOX RNA HELICASES; DENGUE VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE; MICE, INBRED BALB C; NUCLEIC ACID CONFORMATION; RNA, VIRAL; VIRUS DISEASES;

EID: 84937715615     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00845-15     Document Type: Article

References (54)

1. Drinka PJ, Haupt T. 2007. Emergence of rimantadine-resistant virus within 6 days of starting rimantadine prophylaxis with oseltamivir treatment of symptomatic cases. J Am Geriatr Soc 55:923-926. http://dx.doi.org/10.1111/j.1532-5415.2007.01172.x.
2. Bloom JD, Gong LI, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275. http://dx.doi.org/10.1126/science.1187816.
3. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353:2667-2672. http://dx.doi.org/10.1056/NEJMoa054512.
4. Brennan K, Bowie AG. 2010. Activation of host pattern recognition receptors by viruses. Curr Opin Microbiol 13:503-507. http://dx.doi.org/10.1016/j.mib.2010.05.007.
5. Takeuchi O, Akira S. 2009. Innate immunity to virus infection. Immunol Rev 227:75-86. http://dx.doi.org/10.1111/j.1600-065X.2008.00737.x.
6. Wilkins C, Gale M, Jr. 2010. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 22:41-47. http://dx.doi.org/10.1016/j.coi.2009.12.003.
7. Yoneyama M, Fujita T. 2010. Recognition of viral nucleic acids in innate immunity. Rev Med Virol 20:4-22. http://dx.doi.org/10.1002/rmv.633.
8. Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124:783-801. http://dx.doi.org/10.1016/j.cell.2006.02.015.
9. Goubau D, Deddouche S, Reis ESC. 2013. Cytosolic sensing of viruses. Immunity 38:855-869. http://dx.doi.org/10.1016/j.immuni.2013.05.007.
10. Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T, Goldeck M, Schuberth C, Van der Veen AG, Fujimura T, Rehwinkel J, Iskar-patyoti JA, Barchet W, Ludwig J, Dermody TS, Hartmann G, Reis e Sousa C. 2014. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates. Nature 514:372-375. http://dx.doi.org/10.1038/nature13590.
11. Bamming D, Horvath CM. 2009. Regulation of signal transduction by enzymatically inactive antiviralRNAhelicase proteinsMDA5,RIG-I, and LGP2. J Biol Chem 284:9700-9712. http://dx.doi.org/10.1074/jbc.M807365200.
12. Fujita T, Onoguchi K, Onomoto K, Hirai R, Yoneyama M. 2007. Triggering antiviral response by RIG-I-related RNA helicases. Biochimie 89:754-760. http://dx.doi.org/10.1016/j.biochi.2007.01.013.
13. Jiang X, Kinch LN, Brautigam CA, Chen X, Du F, Grishin NV, Chen ZJ. 2012. Ubiquitin-induced oligomerization of the RNA sensors RIG-I and MDA5 activates antiviral innate immune response. Immunity 36:959-973. http://dx.doi.org/10.1016/j.immuni.2012.03.022.
14. Schmidt A, Endres S, Rothenfusser S. 2011. Pattern recognition of viral nucleic acids by RIG-I-like helicases. J Mol Med (Berl) 89:5-12. http://dx.doi.org/10.1007/s00109-010-0672-8.
15. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S. 2005. IPS-1, an adaptor triggering RIG-I-and Mda5-mediated type I interferon induction. Nat Immunol 6:981-988. http://dx.doi.org/10.1038/ni1243.
16. Komuro A, Bamming D, Horvath CM. 2008. Negative regulation of cytoplasmic RNA-mediated antiviral signaling. Cytokine 43:350-358. http://dx.doi.org/10.1016/j.cyto.2008.07.011.
17. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167-1172. http://dx.doi.org/10.1038/nature04193.
18. Belgnaoui SM, Paz S, Hiscott J. 2011. Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. Curr Opin Immunol 23:564-572. http://dx.doi.org/10.1016/j.coi.2011.08.001.
19. Kawai T, Akira S. 2008. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 1143:1-20. http://dx.doi.org/10.1196/annals.1443.020.
20. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, Reis e Sousa C. 2006. RIG-I-mediated antiviral responses to singlestranded RNA bearing 5'-phosphates. Science 314:997-1001. http://dx.doi.org/10.1126/science.1132998.
21. Rehwinkel J, Reis e Sousa C. 2010. RIGorous detection: exposing virus through RNA sensing. Science 327:284-286. http://dx.doi.org/10.1126/science.1185068.
22. Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K, Robb N, Vreede F, Barclay W, Fodor E, Reis e Sousa C. 2010. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 140: 397-408. http://dx.doi.org/10.1016/j.cell.2010.01.020.
23. Takeuchi O, Akira S. 2010. Pattern recognition receptors and inflammation. Cell 140:805-820. http://dx.doi.org/10.1016/j.cell.2010.01.022.
24. Sadler AJ, Williams BR. 2008. Interferon-inducible antiviral effectors. Nat Rev Immunol 8:559-568. http://dx.doi.org/10.1038/nri2314.
25. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-485. http://dx.doi.org/10.1038/nature09907.
26. Sato S, Li K, Kameyama T, Hayashi T, Ishida Y, Murakami S, Watanabe T, Iijima S, Sakurai Y, Watashi K, Tsutsumi S, Sato Y, Akita H, Wakita T, Rice CM, Harashima H, Kohara M, Tanaka Y, Takaoka A. 2015. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 42:123-132. http://dx.doi.org/10.1016/j.immuni.2014.12.016.
27. Goulet ML, Olagnier D, Xu Z, Paz S, Belgnaoui SM, Lafferty EI, Janelle V, Arguello M, Paquet M, Ghneim K, Richards S, Smith A, Wilkinson P, Cameron M, Kalinke U, Qureshi S, Lamarre A, Haddad EK, Sekaly RP, Peri S, Balachandran S, Lin R, Hiscott J. 2013. Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog 9:e1003298. http://dx.doi.org/10.1371/journal.ppat.1003298.
28. Olagnier D, Scholte FE, Chiang C, Albulescu IC, Nichols C, He Z, Lin R, Snijder EJ, van Hemert MJ, Hiscott J. 2014. Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferonindependent stimulation of the innate antiviral response. J Virol 88:4180-4194. http://dx.doi.org/10.1128/JVI.03114-13.
29. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G. 2006. 5'-Triphosphate RNA is the ligand for RIG-I. Science 314:994-997. http://dx.doi.org/10.1126/science.1132505.
30. Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, Coch C, Janke M, Mihailovic A, Wardle G, Juranek S, Kato H, Kawai T, Poeck H, Fitzgerald KA, Takeuchi O, Akira S, Tuschl T, Latz E, Ludwig J, Hartmann G. 2009. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 31:25-34. http://dx.doi.org/10.1016/j.immuni.2009.05.008.
31. Schlee M, Hartmann G. 2010. The chase for the RIG-I ligand-recent advances. Mol Ther 18:1254-1262. http://dx.doi.org/10.1038/mt.2010.90.
32. Olagnier D, Peri S, Steel C, van Montfoort N, Chiang C, Beljanski V, Slifker M, He Z, Nichols CN, Lin R, Balachandran S, Hiscott J. 2014. Cellular oxidative stress response controls the antiviral and apoptotic programs in dengue virus-infected dendritic cells. PLoS Pathog 10:e1004566. http://dx.doi.org/10.1371/journal.ppat.1004566.
33. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
34. Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, Denton M, Legasse AW, Smith PP, Johnson S, Axthelm MK, Vanlandingham DL, Streblow DN, Higgs S, Morrison TE, Diamond MS. 2014. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol 88:8213-8226. http://dx.doi.org/10.1128/JVI.01032-14.
35. Hwang SY, Sun HY, Lee KH, Oh BH, Cha YJ, Kim BH, Yoo JY. 2012. 5'-Triphosphate-RNA-independent activation of RIG-I via RNA aptamer with enhanced antiviral activity. Nucleic Acids Res 40:2724-2733. http://dx.doi.org/10.1093/nar/gkr1098.
36. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. 2004. Innate antiviral responses by means of TLR7-mediated recognition of singlestranded RNA. Science 303:1529-1531. http://dx.doi.org/10.1126/science.1093616.
37. Centers for Disease Control and Prevention. 2009. Update: influenza activity-United States, September 28, 2008-January 31, 2009. MMWR Morb Mortal Wkly Rep 58:115-119.
38. Spurgers KB, Sharkey CM, Warfield KL, Bavari S. 2008. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 78:26-36. http://dx.doi.org/10.1016/j.antiviral.2007.12.008.
39. Binder M, Eberle F, Seitz S, Mucke N, Huber CM, Kiani N, Kaderali L, Lohmann V, Dalpke A, Bartenschlager R. 2011. Molecular mechanism of signal perception and integration by the innate immune sensor retinoic acid-inducible gene-I (RIG-I). J Biol Chem 286:27278-27287. http://dx.doi.org/10.1074/jbc.M111.256974.
40. Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, Hiiragi A, Dermody TS, Fujita T, Akira S. 2008. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acidinducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 205:1601-1610. http://dx.doi.org/10.1084/jem.20080091.
41. Patel JR, Jain A, Chou YY, Baum A, Ha T, Garcia-Sastre A. 2013. ATPase-driven oligomerization of RIG-I on RNA allows optimal activation of type-I interferon. EMBO Rep 14:780-787. http://dx.doi.org/10.1038/embor.2013.102.
42. Uzri D, Gehrke L. 2009. Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J Virol 83:4174-4184. http://dx.doi.org/10.1128/JVI.02449-08.
43. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M, Jr. 2008. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454:523-527. http://dx.doi.org/10.1038/nature07106.
44. Schnell G, Loo YM, Marcotrigiano J, Gale M, Jr. 2012. Uridine composition of the poly-U/UC tract ofHCVRNAdefines non-self recognition by RIG-I. PLoS Pathog 8:e1002839. http://dx.doi.org/10.1371/journal.ppat.1002839.
45. Cui S, Eisenacher K, Kirchhofer A, Brzozka K, Lammens A, Lammens K, Fujita T, Conzelmann KK, Krug A, Hopfner KP. 2008. The C-terminal regulatory domain is the RNA 5'-triphosphate sensor of RIG-I. Mol Cell 29:169-179. http://dx.doi.org/10.1016/j.molcel.2007.10.032.
46. Loo YM, Gale M, Jr. 2011. Immune signaling by RIG-I-like receptors. Immunity 34:680-692. http://dx.doi.org/10.1016/j.immuni.2011.05.003.
47. Luo D, Ding SC, Vela A, Kohlway A, Lindenbach BD, Pyle AM. 2011. Structural insights into RNA recognition by RIG-I. Cell 147:409-422. http://dx.doi.org/10.1016/j.cell.2011.09.023.
48. Lu C, Xu H, Ranjith-Kumar CT, Brooks MT, Hou TY, Hu F, Herr AB, Strong RK, Kao CC, Li P. 2010. The structural basis of 5' triphosphate double-stranded RNA recognition by RIG-I C-terminal domain. Structure 18:1032-1043. http://dx.doi.org/10.1016/j.str.2010.05.007.
49. Kowalinski E, Lunardi T, McCarthy AA, Louber J, Brunel J, Grigorov B, Gerlier D, Cusack S. 2011. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell 147:423-435. http://dx.doi.org/10.1016/j.cell.2011.09.039.
50. Kohlway A, Luo D, Rawling DC, Ding SC, Pyle AM. 2013. Defining the functional determinants for RNA surveillance by RIG-I. EMBO Rep 14: 772-779. http://dx.doi.org/10.1038/embor.2013.108.
51. Peisley A, Wu B, Yao H, Walz T, Hur S. 2013. RIG-I forms signalingcompetent filaments in an ATP-dependent, ubiquitin-independent manner. Mol Cell 51:573-583. http://dx.doi.org/10.1016/j.molcel.2013.07.024.
52. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H. 2005. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79:2910-2919. http://dx.doi.org/10.1128/JVI.79.5.2910-2919.2005.
53. Kulkarni RR, Rasheed MA, Bhaumik SK, Ranjan P, Cao W, Davis C, Marisetti K, Thomas S, Gangappa S, Sambhara S, Murali-Krishna K. 2014. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. J Virol 88:13990-14001. http://dx.doi.org/10.1128/JVI.02273-14.
54. Martinez-Gil L, Goff PH, Hai R, Garcia-Sastre A, Shaw ML, Palese P. 2013. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol 87:1290-1300. http://dx.doi.org/10.1128/JVI.02338-12.